Menu

Recent Interviews

Dirk Graszt, CEO, Clean Logistics SE

Dirk Graszt
CEO | Clean Logistics SE
Trettaustr.32, 21107 Hamburg (DE)

info@cleanlogistics.de

+49-4171-6791300

Interview Clean Logistics: Hydrogen challenge to Daimler + Co.


Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

info@krl.com.sg

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".


Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


12. July 2021 | 10:07 CET

CureVac, XPhyto Therapeutics, Paion - Where are the turning points?

  • Biotechnology
Photo credits: pixabay.com

"Opportunity and risk are two sides of the same coin", that is to say, with great potential returns, there is also the risk of incurring significant price losses. The biotechnology sector, in particular, offers investors a broad universe in which to find lucrative investments. We present three exciting ideas below. Who is winning the race?

time to read: 3 minutes by Carsten Mainitz
ISIN: CUREVAC N.V. O.N. | NL0015436031 , XPHYTO THERAPEUTICS | CA98421R1055 , PAION O.N | DE000A0B65S3


 

Author

Carsten Mainitz

The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

About the author


CUREVAC NV - Hope dies last

It was not long ago that German biotech company CureVac reported the efficacy of its Corona vaccine candidate. A preliminary evaluation of the preparation had indicated efficacy of around 48%. This value has now been finally confirmed. It is a minor catastrophe. Not only is the efficacy significantly lower than that of the competitor products, but the absolute value is also poor, even if some experts try to put this into perspective.

CureVac is currently lagging behind Astra Zeneca, BioNTech/Pfizer, Moderna and Johnson & Johnson. Success is also becoming more difficult due to the ever-increasing number of mutations. The federal government has now announced that it will no longer include a CureVac vaccine in the vaccination campaign. CureVac, like BioNTech and Moderna, relies on mRNA technology, but takes a slightly different approach. Whether this approach has ultimately failed or is permanently inferior to the mRNA technology of BioNTech or Moderna cannot be conclusively assessed at this point.

The German government, which has invested EUR 300 million in CureVac via the development bank KfW and holds a 16% stake, is probably not quite so pleased about the developments. At a price of around EUR 49, the Company is valued at just under EUR 9 billion. Not much has been heard from analysts yet. The experts are probably still busy calculating what the Company is now worth after the severe setback. And it would not be surprising if the experts' opinions differ widely. It remains exciting.

XPHYTO THERAPEUTICS CORP - Innovative and fast

The Canadian Company focuses on accelerating new and innovative medical solutions. Very roughly, the fields include drug formulations, diagnostics, drug delivery and neurological medications. Among other things, the Company specializes in clinical validation and cannabis growth markets in Europe. In addition to testing kits, XPhyto offers solutions to help the human body better absorb medical agents, such as patches, and develops medicines. In addition to a neurological drug, the Canadians are also working with psychedelic agents.

But the Company also provides innovative answers in Corona times. XPhyto has developed a method that allows PCR tests to deliver meaningful results within 20 to 25 minutes. The Company thus scores points for speed. Given the upcoming wave of travel, XPhyto's solution could make the cash register ring.

At the end of Q2, the Canadians reached an agreement with ten testing centers. XPhyto then signed a contract with ten Covid-19 test centers and the first 1,000 Covid-ID Labs (tests) are already in delivery to test centers in Berlin. The test is predestined for airports, clinics, resorts, etc. XPhyto's solution offers a viable approach with timely results - hence high revenue potential for the Company. The Company remains relatively unspecific regarding an outlook but intends to make up for this once the PCR business is up and running.

PAION AG - Good news from China

Paion is also active in an exciting field. The Aachen-based company aims to become a leading specialty pharma company in anesthesia and intensive care by bringing novel products to the market. The activities revolve around innovative active ingredients for outpatient and hospital sedation, anesthesia and intensive care medicine. The lead substance is Remimazolam, an intravenously administered, ultra-short-acting and easily controlled benzodiazepine sedative and anesthetic.

Remimazolam is partnered in several markets outside Europe. The drug is approved for short sedation in the US and EU and for general anesthesia in Japan, South Korea and perhaps soon in China. Recently, the Company announced that its Chinese Remimazolam licensee, Yichang Humanwell, had informed Paion that the Chinese National Medical Products Administration (NMPA) had accepted the marketing authorization application for Remimazolam Besylate in general anesthesia for review. Should further progress be made here, this should certainly have a positive effect on the share price. Currently, the shares are trading at EUR 1.90, valuing the Company at EUR 135 million.


Ultimately, it is always a good idea for investors to build up a diversified portfolio. Then, by spreading the risk, the potential of exciting stocks like XPhyto or Paion can be captured, and the sleepless nights are minimized.


Author

Carsten Mainitz

The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

21. October 2021 | 12:17 CET | by Stefan Feulner

Sartorius, Defence Therapeutics, QIAGEN - Still long potential

  • Biotechnology

Since the outbreak of the Corona pandemic, biotech and pharmaceutical shares have been among the top performers on the stock market. In addition to vaccine producers such as BioNTech and Pfizer, the share price of the US pharmaceutical Company Moderna also multiplied. Other winners included diagnostics companies and laboratory equipment suppliers, process technology specialists and manufacturers of biopharmaceuticals. Biopharmaceuticals promise enormous growth potential even after Corona, especially the market such as gene and cell therapies is growing dynamically at the moment.

Read

20. October 2021 | 11:04 CET | by Armin Schulz

Bayer, Sativa Wellness Group, MorphoSys - Can the pharmaceutical industry benefit from the new German government?

  • Biotechnology

The federal election is over, and the pharmaceutical industry has to adjust to the new political constellation. The industry is facing change. Digitization is an important topic. To not lose even more researchers to foreign countries, approval processes must be accelerated and bureaucracy reduced. If we always acted as decisively as we did during the pandemic, much more could be achieved. The new federal government is flirting with the legalization of cannabis. If this were to happen, the market would probably be huge. The next four years promise to be exciting.

Read

18. October 2021 | 10:44 CET | by Nico Popp

BioNTech, Cardiol Therapeutics, Bayer: Where triple-digit returns beckon

  • Biotechnology

The pandemic is drawing to a close. Vaccination rates are high, and a new wave is - fortunately - not picking up speed. But in this environment, what is happening to many highly acclaimed pandemic stocks? Are vaccine manufacturers still interesting at the moment? We look at how the industry is faring and where opportunities can still be found.

Read